Immune cell infiltration-associated signature in colon cancer and its prognostic implications

Dan Deng1,2,*, Xin Luo1,*, Sifang Zhang2, Zhijie Xu3,4

1Department of Cardiology, Zhuzhou Central Hospital, Zhuzhou 412007, China
2Department of Integrated Traditional Chinese and Western Internal Medicine, The Second Xiangya Hospital of Central South University, Changsha 410012, China
3Department of Pathology, Xiangya Hospital of Central South University, Changsha 410008, China
4National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China
*Equal contribution

Correspondence to: Sifang Zhang, Zhijie Xu; email: sifangzhang2005@csu.edu.cn, xzj1322007@csu.edu.cn

Keywords: prognosis, colon cancer, immune cell infiltration, tumor mutation burden, immunotherapy

Received: February 17, 2021 Accepted: July 15, 2021 Published: August 4, 2021

ABSTRACT

Tumor immune cell infiltration (ICI) has been reported in various studies to be correlated with tumor diagnosis, clinical treatment sensitivity and prognosis. It is an important direction to study the characteristics of immune cell infiltration and develop new prognostic markers to improve the treatment of colon cancer. In this paper, we systematically analyzed the ICI characteristics and obtained three ICI clusters. Then, the ICI scores were constructed and its prognostic implications were discussed. From the results, the ICI score patterns were linked to a great survival difference (p<0.001). A high ICI score was characterized by a higher fraction of plasma cells, CD8+ T cells, memory resting CD4+ T cells, monocytes, eosinophils and dendritic cells, which had better prognosis. Macrophages and neutrophils were increased in low ICI score patients with decreased overall survival. Immune checkpoint molecules (PDCD1, CD274, LAG3, ID01, CTLA-4, TIGHT and HAVCR2) were found to be significantly overexpressed in the low ICI score subgroup. In addition, we also studied the correlation between the tumor mutation burden (TMB) and ICI score. This study indicated the ICI score could serve as a potential prognostic biomarker for colon cancer patients' immunotherapy.

INTRODUCTION

Colorectal cancer (CRC) is the third most common cancer and accounts for over 8% of all deaths annually worldwide, and colon cancer is its main type [1, 2]. Most colon cancer cases and deaths are attributable to age, physical inactivity, obesity, and genetic and environmental factors [3, 4]. Conventional treatments for colon cancer, including surgery, radiotherapy and chemotherapy, which are invasive treatments, may have a greater impact on patient quality of life [5]. At present, immunotherapy has shown strong antitumor activity in the treatment of many solid tumors, such as melanoma, nonsmall cell lung, renal and prostate cancer [6]. However, neither PD-1/L1 nor CTLA-4 has yet been confirmed to have relevant efficacy in unselected colon cancer, and only the subgroups of deficient mismatch repair (dMMR) or microsatellite instable high (MSI-H) tumors of colon cancer are amenable to checkpoint inhibition [7, 8]. It is necessary to develop new therapeutic markers so that ideal colon cancer subgroups for immunotherapy can be identified.

More and more studies have shown that the TME is connected to the development and metastasis of tumors and significantly affects their diagnosis, survival outcome and clinical treatment sensitivity [9–11]. In-depth study of tumor immune cell infiltration (ICI) and...
quantification may provide valuable prognostic molecular markers and prognostic models for tumor biology [12]. Naito first described cytotoxic CD8+ T cell infiltration in the immune microenvironment of colon cancer as an independent prognostic factor [13]. The prognostic value of cytotoxic and memory T cells in primary colon cancer tumors has been widely reported [14]. Tumor associated macrophages secrete immunosuppressive cytokines, such as interleukin-10 (IL-10) and transforming growth factor-β (TGF-β), can promote the growth and development of tumor [15].

Novel and effective classification methods based on immune infiltrating cells and immune-related genes maybe the key to hierarchical treatment for colon cancer patients [16, 17]. Nowadays, there have been numerous studies searching for prognostic biomarker by integrating multiple elements into a model for prognosis prediction [18]. For example, a prognosis model was conducted based on 12 differential expressed immune genes between healthy and tumor samples [19]. In addition, using Cox analysis, several immune infiltration prognostic signatures based on 22 types of immune cells were build and could serve as important prognostic methods for colon cancer [20–22]. However, the roles of immune infiltration cells and reliable immune-related prognostic signature in colon cancer remain to be fully characterized. In this paper, we systematically analyzed the characteristics of the ICI for colon cancer and used this therapeutic marker to classify and predict the outcome. This marker could be a potential prognostic biomarker and predictive indicator for colon cancer patients’ immunotherapy.

RESULTS

Tumor ICI and immunophenotyping

The colon cancer samples were downloaded from TCGA and GSE17536 [23] datasets. In the subsequent analysis, the CIBERSORT and ESTIMATE algorithm were used to quantify the infiltration level of immune cells in colon cancer tissues [24, 25]. The colon cancer patients were divided into three distinct subtypes (ICI clusters A-C) by the K-means algorithm. To analyze the expression of immune cells according to different immune subtypes and clinical characteristics, a heat map of 22 kinds of immune cells associated with different survival statuses, stages, ages and subtypes was drawn (Figure 1).

Figure 2A shows the Kaplan-Meier curve for different ICI clusters, and the patients exhibiting these three ICI clusters show statistically significant survival differences (p=0.012). After that, the correlation between immune cells was analyzed, and the results showed that CD8+ T cells had the greatest negative correlation with M0 macrophages and the largest positive correlation with M1 macrophages, the immune scores and stromal scores were negatively correlated with macrophages (Figure 2B). Figure 2C indicates the difference in immune cell contents in ICI clusters of colon cancer patients. ICI cluster A had the best overall survival (OS) and was

![Figure 1. Heat map. Rows represent colon cancer samples, columns represent tumor-infiltrating immune cells, red indicates high expression, and blue indicates low expression.](image-url)
marked by the highest fraction of plasma cells, memory resting CD4+ T cells, dendritic cells, monocytes and eosinophils. ICI cluster B exhibited a significant increase in regulatory T cells and M0 macrophages. In contrast, CD8+ T cells, memory-activated CD4+ T cells, follicular helper T cells, activated NK cells, M1 macrophages and resting mast cells have the largest proportions in ICI cluster C. Then, we found that the expression level of PD-L1, an important immune checkpoint molecule for colon cancer, presented a significant difference between different ICI clusters, and ICI cluster C was characterized by the highest expression level with poor prognosis (Figure 2D) [26].

Genotyping
To reveal the potential biological characteristics of distinct subtypes, differentially expressed genes (DEGs) were identified among these ICI clusters by the limma package in R software, and 113 DEGs were obtained. The DEGs positively correlated with the gene cluster were marked as type I, and the rest were designated as type II. According to these DEGs, the colon cancer samples were classified into two groups by the K-means algorithm with small intragroup differences and the large differences between distinct subgroups, as shown in Figure 3A; these two groups were named gene cluster

![Genotyping Diagram](image)

**Figure 2. ICI and immunophenotyping for colon cancer patients.** (A) Kaplan-Meier curves for the three ICI clusters (Log-rank test, p=0.012). (B) Correlation analysis of tumor-infiltrating immune cells. Blue represents negative correlation, and red represents positive correlation. (C) Box plot showing the contents of tumor-infiltrating immune cells within three ICI clusters (Kruskal-Wallis test, ***p<0.001; **p<0.01; *p<0.05). (D) Expression analysis of PD-L1 within three ICI clusters (Kruskal-Wallis test, ***p<0.001; **p<0.01; *p<0.05).
A (n=323) and B (n=265). The Kaplan-Meier curve indicated that the patients with the gene cluster A profile had better OS than those with gene cluster B (Figure 3B, p=0.003). Figure 3C shows the heat map of DEGs with different subgroups and clinical statuses.

ICI score prognostic signature

In this section, 90 characteristic genes were screened from the DEGs by the Boruta package in R software (Supplementary Table 1). After that, the scores of type I (n=62) and type II (n=28) characteristic genes were calculated by principal component analysis (PCA), named $S_{PCA1}$ and $S_{PCA2}$, respectively. The ICI score of each colon cancer patient could be obtained as follows:

$$ICI\ score = S_{PCA1} - S_{PCA2}$$

The colon cancer patients could be divided into high (n=348) and low (n=240) ICI score subgroups with the optimal cutoff value. The survival rate of the high ICI score subgroup was significantly higher than that of the low ICI score subgroup at the same time point, suggesting that colon cancer patients with high ICI scores had a better prognosis, as shown in Figure 4A (p<0.001). Moreover, it could be found that there was a significant difference in survival between high and low ICI score patients in TCGA (p=0.001) and GSE17536 (p=0.02), respectively. The high ICI score subtype was marked by a high proportion of plasma cells, CD8+ T cells, memory resting CD4+ T cells, monocytes, and so on.

Figure 3. Genotyping analysis. (A) In a cluster analysis based on the K-means algorithm, the colon cancer patients were classified into two subgroups, designated gene clusters (A, B). (B) The Kaplan-Meier curves for patients with gene clusters (A, B) (Log-rank test, p=0.003). (C) Heat map of DEGs. Rows represent colon cancer samples with different subtypes and clinical status; columns represent tumor-infiltrating immune cells.
dendritic cells and eosinophils. In the low ICI score subtype, macrophages and neutrophils contributed a relatively greater fraction. (Figure 4B). We further analyzed the immune activity of the immune checkpoint relevant molecules in high and low ICI score subgroups (LAG3, PDCD1/PD-1, IDO1, CD274/PD-L1, CTLA-4, TIGHT, HAVCR2) [27, 28]. We found that all immune checkpoint molecules were significantly overexpressed in the low ICI score subgroup, which had poor outcomes (Figure 4C). The ICI score showed statistical differences between alive and dead (p=0.0023), stage I-II and III-IV (p=0.0028) patients, in which surviving and stage I-II patients associated to higher ICI scores, however, there was no obviously difference in gender and age (Figure 4D).

Gene Ontology (GO) enrichment analysis was used to define the different biological functions in different DEG types. The results showed that type I characteristic DEGs were mainly enriched in extracellular matrix, extracellular structure organization, collagen-containing extracellular matrix and extracellular matrix structural

---

Figure 4. Analysis of the ICI score. (A) Kaplan-Meier curves for colon cancer patients with high and low ICI scores (Log-rank test). All patients (p<0.001); TCGA (p=0.001); GSE17536 (p=0.02). (B) Boxplot showing the contents of tumor-infiltrating immune cells within the high and low ICI score subgroup (Kruskal-Wallis test, ***p< 0.001, **p<0.01, *p<0.05). (C) immune checkpoint gene expression analysis for colon cancer in high and low ICI score subgroups. (Kruskal-Wallis test, ***p<0.001, **p<0.01, *p<0.05). (D) Boxplots showing the difference of ICI scores with different Clinical characteristics (Wilcoxon test). Gender (p=0.58); Age (p=0.14); Stage (p=0.0028); Fustat (p=0.0023).
constituent (Figure 5A). Type II characteristic DEGs were primarily enriched in antimicrobial humoral response, humoral immune response, apical part of cell and carbohydrate binding (Figure 5B). The results of GSEA showed that aminoacyl tRNA biosynthesis, glyoxylate and dicarboxylate metabolism, butanoate metabolism, citrate cycle/TCA cycle, and retinol metabolism were enriched in the high ICI score subgroup, whereas beta alanine metabolism, tight junction, regulation of actin cytoskeleton, arrhythmogenic right ventricular cardiomyopathy (ARVC), and focal adhesion were enriched in the low ICI score subgroup (Figure 6).

**Association analysis of the TMB and ICI score**

This section analyzed the internal relationship between ICI score and tumor mutation burden (TMB), considering TMB is a potential predictor of response to

---

**Figure 5. GO annotations for characteristic DEGs.** (A) Bar chart for type I characteristic genes. (B) Bar chart for type II characteristic genes. The abscissa represents the number of characteristic genes, and the ordinate shows the GO term. BP represents biological process, CC represents cell component, and MF represents molecular function.

---

**Figure 6. GSEA enrichment plots.**
immune checkpoint inhibitors in MSI-H colon cancer [29]. First, we downloaded the TMB data of colon cancer patients from TCGA database and classified these patients into high (n=186) and low (n=174) TMB subtypes. As shown in Figure 7A, the OS of the low TMB group was better (p=0.043). The Kaplan-Meier curve showed significant differences in OS among the combined subgroups (H-TMB+H-ICI score, H-TMB+L-ICI score, L-TMB+H-ICI score and L-TMB+L-ICI score), and the ICI score subgroups showed significant survival differences in both the high and low TMB subtypes (Figure 7B, p=0.002). Among them, the L-TMB+H-ICI subgroup patients had the best prognosis. To explore the intrinsic relationship between the TMB and ICI scores, difference and correlation analyses were conducted between TMB and ICI scores. The correlation analysis confirmed that the ICI score was not obviously correlated with the TMB, as shown in Figure 7C. Further, the mutation annotation files of TCGA cohort between the high and low ICI score subgroups were analyzed, and the top 25 driver genes with the highest alteration frequency are shown in Figure 7D. These analyses revealed that 8 driver genes (APC, TTN, TP53, KRAS, LRP2, FAT4, OBSCN, LRP2) were clearly different in alteration frequency (the value of difference >= 7%) between the two ICI score subgroups, but only TP53 showed a statistically significant difference (Table 1).

Figure 7. Association analysis of the ICI score and TMB. (A) Kaplan-Meier curve for high and low TMB colon cancer patients (Log-rank test, p=0.043). (B) Kaplan-Meier curve for combined subgroups of the ICI score and TMB (Log-rank test, p=0.002). (C) Correlation analysis between the TMB and ICI score, Spearman correlation coefficient = -0.033, p=0.53. (D) Waterfalls plot of driver gene mutations in the high and low ICI score subtypes. Rows represent colon cancer samples with different subgroups, columns represent genes, and the mutation type is indicated by different colors.
Table 1. The top 20 mutation genes were clearly different in alteration frequency between the two ICI score subgroups in colon cancer patients.

| Gene  | H-mutation (%) | L-mutation (%) | p-value |
|-------|----------------|----------------|---------|
| TP53  | 99(48%)        | 95(62%)        | 0.0139  |
| SDK1  | 19(9%)         | 27(18%)        | 0.0295  |
| RNF43 | 16(8%)         | 24(16%)        | 0.0303  |
| DNAH7 | 12(6%)         | 25(16%)        | 0.0023  |
| DSCAM | 14(7%)         | 21(14%)        | 0.0469  |
| PTPRT | 13(6%)         | 21(14%)        | 0.0301  |
| PDZD2 | 12(6%)         | 21(14%)        | 0.0184  |
| DOCK2 | 11(5%)         | 19(12%)        | 0.0290  |
| NIPBL | 11(5%)         | 19(12%)        | 0.0290  |
| PKD1L1| 9(4%)          | 18(12%)        | 0.0161  |
| ZNF423| 10(5%)         | 17(11%)        | 0.0453  |
| NBEAL2| 8(4%)          | 18(12%)        | 0.0086  |
| GRP158| 9(4%)          | 17(11%)        | 0.0269  |
| TRIOBP| 8(4%)          | 17(11%)        | 0.0150  |
| PKDREJ| 9(4%)          | 16(10%)        | 0.0440  |
| MKI67 | 9(4%)          | 16(10%)        | 0.0440  |
| ERICH3| 9(4%)          | 16(10%)        | 0.0440  |
| SIPA1L1| 8(4%)        | 16(10%)        | 0.0254  |
| SHPRH | 8(4%)          | 16(10%)        | 0.0254  |
| CDH18 | 7(4%)          | 16(10%)        | 0.0137  |

**DISCUSSION**

Increasing evidence shows that the TME is closely related to the tumor growth, invasion and metastasis of colon cancer [30, 31]. At present, the construction of these immune infiltration prognostic signatures for colon cancer mainly focuses on the identification prognosis-related molecules by Cox regression analysis [19–21]. ICI scores are obtained from unsupervised clustering and PCA algorithm between patients with different ICI landscape. Moreover, its prognostic value for immunotherapy have been discussed in head and neck squamous cell carcinoma [32]. However, the detailed functions and features of ICI scores have not been elucidated in colon cancer.

From the immunophenotyping results, the ICI cluster A subgroup had the best prognosis, with the highest proportions of plasma cells, memory resting CD4⁺ T cells, dendritic cells, monocytes and eosinophils. However, increased infiltration of CD8⁺ T cells, memory-activated CD4⁺ T cells, follicular helper T cells, activated NK cells, M1 macrophages and resting mast cells were correlated with decreased OS. To quantify the ICI patterns of individual tumors in colon cancer, the ICI score based on immune-related genes and tumor ICI was used to predict prognosis, and it showed the best survival differences compared with immunophenotyping and genotyping. We found plasma cells, CD8⁺ T cells, memory resting CD4⁺ T cells, monocytes and dendritic cells exhibited relatively higher infiltration levels in the high ICI score patients with increased OS. In the past research, CD4⁺ and CD8⁺ T cells have been well documented to play important roles in antitumor immune responses and as clinically useful prognostic markers in colon cancer [33–35], dendritic cells can present tumor antigens and activate the naïve T cells [36], and the increase of plasma cells indicates an obvious humoral immune response [37]. These results indicating an obvious an antitumor immune response in the high ICI score subgroup. At the same time, CD8⁺ T cells and M0 macrophages showed a large negative correlation in the correlation analysis of tumor infiltrating cells. These results suggest that the low level of ICI and the increased expression of tumor-associated macrophages may contribute to the poor prognosis of patients with colon cancer. From the GO enrichment analysis, type I characteristic DEGs were mainly distributed in the functions related to the extracellular matrix and type II characteristic DEGs were mainly enriched in antimicrobial humoral response, humoral immune response and apical part of cell.

Immunotherapy has become a major effective treatment modality for multiple types of solid cancers [38, 39]. This study analyzed the expression of PD-L1 in different ICI clusters and found that the highest expression of PD-L1 in ICI cluster C patients with poor prognosis, and PD-
1/L1 has been identified as a possible target for immunotherapy in MSI-H/dMMR colon cancer [20, 40]. In addition, potential and known immune checkpoint molecules (PDCD1, CD274, LAG3, IDO1, CTLA-4, TIGHT and HAVCR2) were found to be significantly overexpressed in the low ICI score subgroup associated with poor outcomes. The overexpression of immune checkpoint molecules on immune cells will inhibit the function of immune cells, which causes the body to be unable to produce an effective antitumor immune response, and suppress the immune function of low ICI score patients [41, 42]. For example, the high expression of PD-L1 in tumor tissue inhibits the function of tumor infiltrating CD8⁺ T cells [43], and the CTLA-4 will exert its inhibitory functions on the initial T cells activation, leading to tumor immune escape [44].

High TMB is generally associated with poor OS [45], this is consistent with our research result, although the survival difference between the high and low TMB colon cancer patients was not remarkable. It is worth noting higher TMB (highest 20% in each histology and the cut-point was 52.2MB) is associated with better OS for immune checkpoint inhibitor treatments of colon cancer [46]. These may be related to the overall low TMB in our samples. In the association analysis of ICI score and TMB, the ICI score subgroups showed notable survival differences within both high and low TMB subtypes, and the L-TMB+H-ICI score subgroup patients had the best OS. Multiple genes, including TP53, one of the most common type of mutations in colon cancer, showed significant differences in mutation frequency between patients with high and low ICI scores. In the previous studies, TP53 mutation has been confirmed to be related to immune response and progression of colon cancer [47, 48].

Our study results implied that a high ICI score was characterized by a higher fraction of plasma cells, CD8⁺ T cells, memory resting CD4⁺ T cells, monocytes, eosinophils and dendritic cells with increased OS. And the low level of T cells infiltration, overexpressed macrophages, neutrophils and multiple immune checkpoint molecules may lead to poor prognosis in colon cancer. In summary, the ICI score could be a potential prognostic biomarker for colon cancer patients’ immunotherapy. However, the findings demand further evaluated by a larger cohort of samples and clinical trial.

MATERIALS AND METHODS

Colon cancer data and samples

This paper was conducted in R 4.0.3 software (https://www.r-project.org/). The level-three transcriptome RNA-sequencing data (HTSeq-FPKM) and clinical data of 473 primary colon cancer samples were derived from TCGA database (https://portal.gdc.cancer.gov/). At the same time, 177 colon cancer samples were downloaded from the GEO (GSE17536, https://www.ncbi.nlm.nih.gov/geo/) database. After that, the expression data downloaded from these two databases were sorted and annotated with Perl software. To eliminate the differences in the data measured in these two databases, the FPKM value expressed in TCGA database was transformed into transcripts per kilobase million (TPM) using the limma package in R. Then, the sample expression data matrixes from TCGA and the GEO database were combined for subsequent analysis.

CIBERSORT and ESTIMATE algorithm

In this section, the CIBERSORT package of R software was used to quantify the infiltration level of immune cells in colon cancer patients. The number of simulations was set as perm=1000, and the screening criterion was a p-value<0.05. The immune and stromal score and their comprehensive score were evaluated by ESTIMATE for each colon cancer sample.

Immunophenotyping and genotyping

The ConsensClusterPlus package of R software and the K-means algorithm were used to classify colon cancer patients, and the maximum K was set to 9 to select the optimal classification. The classification of colon cancer patients mainly includes immunophenotyping and genotyping, and the subgroups were called ICI clusters and gene clusters, respectively. ICI cluster classification was based on the content of immune cells, and gene clusters were based on the expression of DEGs.

The DEGs identified and ICI score signature constructed

The limma package was used to identify DEGs between different ICI clusters with the following criteria: log₂ FC>1 and FDR<0.05. According to the expression of DEGs in gene clusters, DEGs were divided into two types. The DEGs were marked as type I if their expression was positively correlated with genotyping, and the rest were marked as type II. The Boruta package was used to find the characteristic genes. Then, using the PCA algorithm to calculate the score of characteristic genes for type I and type II, marked S_{PCA I} and S_{PCA II}, respectively. The ICI score of each colon cancer patient could be calculated as:

$$ICI\ score=S_{PCA I}−S_{PCA II}$$

Then, the surv_cutpoint function was used to analyze the ICI score of patients and find the optimal cutoff
point. The colon cancer patients were divided into high and low ICI score subgroups based on this cutoff point.

**Survival analysis and immunocyte difference analysis**

To study whether the different subgroups were related to the prognosis in colon cancer patients, Kaplan-Meier survival curves of different subgroups were drawn, and the log rank test was used to evaluate whether the differences were statistically significant. All Kaplan-Meier survival analysis excluded patients whose survival time was less than 30 days. Moreover, the differences in fractions of tumor infiltrating immune cells in different clusters were analyzed in this paper by Kruskal-Wallis test.

**GO function enrichment analysis and GSEA**

GO functional analysis was carried out to explore the biological functions of ICI DEGs for colon cancer, and bar plots for type I and type II characteristic genes were drawn. The Gene Set Enrichment Analysis (GSEA) of high and low ICI score subgroups was conducted by GSEA v4.1 software (http://www.gsea-msigdb.org/gsea/index.jsp), and the number of permutations was set to 1000.

**Association analysis of the ICI score and TMD**

The mutation data for the colon cancer patients were downloaded from TCGA database. The TMB was analyzed by counting the total number of non-synonymous mutations in the colon cancer sample. Then, four subtypes were obtained based on the combination of the TMB the ICI score: H-TMB+H-ICI score, H-TMB+L-ICI score, L-TMB+H-ICI score and L-TMB+L-ICI score. Using maftools package of R software to identify the driver genes, and the top 25 driver genes with the highest alteration frequency were shown in waterfall plots and top 20 mutation genes with statistical difference were listed.

**AUTHOR CONTRIBUTIONS**

Dan Deng and Xin Luo provided methodology, performed the analysis and wrote the original draft. Sifang Zhang carried out supervision, data interpretations and helped data discussion. Sifang Zhang and Zhijie Xu reviewed and revised the manuscript. All authors read and approved the final manuscript.

**CONFLICTS OF INTEREST**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

**FUNDING**

This work was supported by the Hunan Provincial Natural Science Foundation of China (No. 2018JJ2595), and Research projects of traditional Chinese medicine of Hunan Province (No. 2020012).

**REFERENCES**

1. Castells A. Hereditary forms of colorectal cancer. Gastroenterol Hepatol. 2016 (Suppl 1); 39:62–67. [https://doi.org/10.1016/S0210-5705(16)30176-5](https://doi.org/10.1016/S0210-5705(16)30176-5) PMID:27888866

2. Ma H, Brosens LA, Offerhaus GJ, Giardiello FM, de Leng WW, Montgomery EA. Pathology and genetics of hereditary colorectal cancer. Pathology. 2018; 50: 49–59. [https://doi.org/10.1016/j.jpathol.2017.09.004](https://doi.org/10.1016/j.jpathol.2017.09.004) PMID:29169633

3. Thanikachalam K, Khan G. Colorectal Cancer and Nutrition. Nutrients. 2019; 11:164. [https://doi.org/10.3390/nu11010164](https://doi.org/10.3390/nu11010164) PMID:30646512

4. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020; 70:145–64. [https://doi.org/10.3322/caac.21601](https://doi.org/10.3322/caac.21601) PMID:32133645

5. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist. 2005; 10:250–61. [https://doi.org/10.1634/theoncologist.10-4-250](https://doi.org/10.1634/theoncologist.10-4-250) PMID:15821245

6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leuring PD, Spigel DR, Antonia SJ, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366:2443–54. [https://doi.org/10.1056/NEJMoa1200690](https://doi.org/10.1056/NEJMoa1200690) PMID:22658127

7. Stein A, Fulprecht G. Immunotherapy of Colon Cancer. Oncol Res Treat. 2018; 41:282–85. [https://doi.org/10.1159/000488918](https://doi.org/10.1159/000488918) PMID:29705788

8. Asaoka Y, Ijichi H, Koike K. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 373:1979. [https://doi.org/10.1056/NEJMc1510353](https://doi.org/10.1056/NEJMc1510353) PMID:2659583

9. Demircan NC, Boussios S, Taci T, Öztürk MA. Current and future immunotherapy approaches in ovarian cancer. Ann Transl Med. 2020; 8:1714. [https://doi.org/10.21037/atm-20-4499](https://doi.org/10.21037/atm-20-4499) PMID:33490226
10. Koi M, Carethers JM. The colorectal cancer immune microenvironment and approach to immunotherapies. Future Oncol. 2017; 13:1633–47. 
https://doi.org/10.2217/fon-2017-0145 
PMID: 28829193

11. Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The Immunoscore: Colon Cancer and Beyond. Clin Cancer Res. 2020; 26:332–39. 
https://doi.org/10.1158/1078-0432.CCR-18-1851 
PMID: 31413009

12. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014; 232:199–209. 
https://doi.org/10.1002/path.4287 
PMID: 24122236

13. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58:3491–94. 
PMID: 9721846

14. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pagès F, Galon J. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011; 29:610–18. 
https://doi.org/10.1200/JCO.2010.30.5425 
PMID: 21245428

15. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41: 49–61. 
https://doi.org/10.1016/j.immuni.2014.06.010 
PMID: 25035953

16. Bramsen JB, Rasmussen MH, Ongen H, Mattesen TB, Ørntoft MW, Árnadóttir SS, Sandoval J, Laguna T, Vang S, Øster B, Lamy P, Madsen MR, Laurberg S, et al. Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer. Cell Rep. 2017; 19:1268–80. 
https://doi.org/10.1016/j.celrep.2017.04.045 
PMID: 28494874

17. Pagès F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, Nagtegaal ID, Vink-Börger E, Hartmann A, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391:2128–39. 
https://doi.org/10.1016/S0140-6736(18)30789-X 
PMID: 29754777

18. Ye L, Zhang T, Kang Z, Guo G, Sun Y, Lin K, Huang Q, Shi X, Ni Z, Ding N, Zhao KN, Chang W, Wang J, et al. Tumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer. Front Immunol. 2019; 10:2368. 
https://doi.org/10.3389/fimmu.2019.02368 
PMID: 31681276

19. Miao Y, Wang J, Ma X, Yang Y, Mi D. Identification prognosis-associated immune genes in colon adenocarcinoma. Biosci Rep. 2020; 40:BSR20201734. 
https://doi.org/10.1042/BSR20201734 
PMID: 33140821

20. Zhang X, Zhao H, Shi X, Jia X, Yang Y. Identification and validation of an immune-related gene signature predictive of overall survival in colon cancer. Aging (Albany NY). 2020; 12:26095–120. 
https://doi.org/10.18632/aging.202317 
PMID: 33401247

21. Zhou R, Zhang J, Zeng D, Sun H, Rong X, Shi M, Bin J, Liao Y, Liao W. Immune cell infiltration as a biomarker for the diagnosis and prognosis of stage I–III colon cancer. Cancer Immunol Immunother. 2019; 68: 433–42. 
https://doi.org/10.1007/s00262-018-2289-7 
PMID: 30564892

22. Peng D, Wang L, Li H, Cai C, Tan Y, Xu B, Le H. An immune infiltration signature to predict the overall survival of patients with colon cancer. IUBMB Life. 2019; 71:1760–70. 
https://doi.org/10.1002/iub.2124 
PMID: 31301220

23. Smith JJ, Deane NG, Wu F, Merchant NB, Zhang B, Jiang A, Lu P, Johnson JC, Schmidt C, Bailey CE, Eschrich S, Kis C, Levy S, et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology. 2010; 138:958–68. 
https://doi.org/10.1053/j.gastro.2009.11.005 
PMID: 19914252

24. Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12:453–57. 
https://doi.org/10.1038/nmeth.3337 
PMID: 25822800

25. Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Trehvilo V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. 
https://doi.org/10.1038/ncomms3612 
PMID: 24113773

26. Payandeh Z, Khalili S, Somi MH, Mard-Soltani M, Baghbanzadeh A, Hajiasgharzadeh K, Samadi N, ...
Baradaran B. PD-1/PD-L1-dependent immune response in colorectal cancer. J Cell Physiol. 2020; 235:5461–75. https://doi.org/10.1002/jcp.29494 PMID:31960962

27. Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA Jr. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019; 16:361–75. https://doi.org/10.1038/s41575-019-0126-x PMID:30886395

28. Wu X, Gu Z, Chen Y, Chen B, Chen W, Weng L, Liu X. Application of PD-1 Blockade in Cancer Immunotherapy. Comput Struct Biotechnol J. 2019; 17:661–74. https://doi.org/10.1016/j.csbj.2019.03.006 PMID:31205619

29. Schrock AB, Ouyang C, Sandhu J, Sokel E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019; 30:1096–103. https://doi.org/10.1093/annonc/mdz134 PMID:31038663

30. Hao Y, Hu P, Zhang J. Genomic analysis of the prognostic effect of tumor-associated neutrophil-related genes across 15 solid cancer types: an immune perspective. Ann Transl Med. 2020; 8:1507. https://doi.org/10.21037/atm-20-6629 PMID:33313252

31. Camus M, Tosolini M, Mlecnik B, Pagès F, Kirilovsky A, Berger A, Costes A, Bindea G, Charoentong P, Bruneval P, Trajanoski Z, Fridman WH, Galon J. Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res. 2009; 69:2685–93. https://doi.org/10.1158/0008-5472.CAN-08-2654 PMID:19258510

32. Zhang X, Shi M, Chen T, Zhang B. Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy. Mol Ther Nucleic Acids. 2020; 22:298–309. https://doi.org/10.1016/j.omtn.2020.08.030 PMID:32320435

33. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoué F, Bruneval P, Cugnenc PH, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006; 313:1960–64. https://doi.org/10.1126/science.1129139 PMID:17008531

34. Laghi L, Bianchi P, Miranda E, Balladore E, Pacetti V, Grizzi F, Allavenna P, Torri V, Repici A, Santoro A, Mantovani A, Roncalli M, Malesci A. CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study. Lancet Oncol. 2009; 10:877–84. https://doi.org/10.1016/S1470-2241(09)70186-X PMID:19656725

35. Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, Nizze H, Barten M. Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol. 2004; 35:808–16. https://doi.org/10.1016/j.humpath.2004.01.022 PMID:15257543

36. Gessani S, Belardelli F. Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells. Cancers (Basel). 2019; 11:1491. https://doi.org/10.3390/cancers11101491 PMID:31623355

37. Pioli PD. Plasma Cells, the Next Generation: Beyond Antibody Secretion. Front Immunol. 2019; 10:2768. https://doi.org/10.3389/fimmu.2019.02768 PMID:31824518

38. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161:205–14. https://doi.org/10.1016/j.cell.2015.03.030 PMID:25860605

39. Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019; 110:312–18. https://doi.org/10.1016/j.biopha.2018.11.105 PMID:30522017

40. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015; 5:43–51. https://doi.org/10.1158/2159-8290.CD-14-0863 PMID:25358689

41. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, Miller ML, Rekhtman N, Moreira AL, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348:124–28. https://doi.org/10.1126/science.aaa1348 PMID:25765070

42. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G,
Ciobanu V, West AN, Carmona M, Kivork C, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515:568–71. https://doi.org/10.1038/nature13954 PMID:25428505

43. Fiegle E, Doleschel D, Koletnik S, Rix A, Weiskirchen R, Borkham-Kamphorst E, Kiessling F, Lederle W. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer. Neoplasia. 2019; 21:932–44. https://doi.org/10.1016/j.neo.2019.07.006 PMID:31412307

44. van Willigen WW, Bloemendal M, Gerritsen WR, Schreibelt G, de Vries IJ, Bol KF. Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. Front Immunol. 2018; 9:2265. https://doi.org/10.3389/fimmu.2018.02265 PMID:30327656

45. Wu HX, Wang ZX, Zhao Q, Chen DL, He MM, Yang LP, Wang YN, Jin Y, Ren C, Luo HY, Wang ZQ, Wang F. Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers. Ann Transl Med. 2019; 7:640. https://doi.org/10.21037/atm.2019.10.116 PMID:31930041

46. Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51: 202–06. https://doi.org/10.1038/s41588-018-0312-8 PMID:30643254

47. Zhao X, Liu J, Liu S, Yang F, Chen E. Construction and Validation of an Immune-Related Prognostic Model Based on TP53 Status in Colorectal Cancer. Cancers (Basel). 2019; 11:1722. https://doi.org/10.3390/cancers11111722 PMID:31689990

48. IJspeert JE, Vermeulen L, Meijer GA, Dekker E. Serrated neoplasia-role in colorectal carcinogenesis and clinical implications. Nat Rev Gastroenterol Hepatol. 2015; 12:401–09. https://doi.org/10.1038/nrgastro.2015.73 PMID:25963511
**Supplementary Table**

**Supplementary Table 1.** The 90 characteristic genes were screened by the Boruta package in R software.

| Type   | Gene                                                                 |
|--------|----------------------------------------------------------------------|
| I (n=62) | MMP9, ITGBL1, THBS2, COMP, BGN, GAS1, SFRP2, FNDC1, CYP1B1, COL10A1, SFRP4, MARCO, COL11A1, SPP1, FN1, AEBP1, ASPN, PRELP, COL1A1, THBS4, DES, NKG7, CCL5, IDO1, CXCL9, CXCL10, GZMA, CDH11, LTBP1, DPYSL3, MSRB3, ANTXR1, COL8A1, FIBIN, OLFML2B, COL8A2, VCAN, COL12A1, MATN3, FBN1, COL5A2, LRRC15, INHBA, COL5A1, FAP, MFAP5, MXRA5, SULF1, TAGLN, COL3A1, PLN, LUM, COL1A2, MGP, MMP11, SPOCK1, OLR1, GBP4, POSTN, CTHRC1, CNN1, MYH11 |
| II (n=28) | CLCA1, ITLN1, FCGBP, SPINK4, MUC2, CLCA4, REG4, ZG16, B3GNT6, PIGR, HEPACAM2, DUOXA2, LCN2, DUOX2, ATOH1, CA4, IGLJ3, CEACAM7, UGT2B17, VSIG2, MS4A12, NXPE4, TCN1, REG1A, OLFM4, REG3A, DEFA5, SLC26A3 |